Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 34591-34600 Newer>

The Motley Fool February 10, 2009 Rick Aristotle Munarriz	Who Will Buy Sirius XM Radio? Satellite television's Echostar can't be the only one interested in satellite radio.
The Motley Fool February 10, 2009 Dan Caplinger	All-Purpose Stocks You Shouldn't Miss Look beyond your usual horizons and get the best of all worlds with these stocks.
The Motley Fool February 10, 2009 Brian Orelli	Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma.
The Motley Fool February 10, 2009 Tim Beyers	Why Akamai Doubled Shares of Akamai surged last week after the company's reported results crushed Street estimates.
The Motley Fool February 10, 2009 David Lee Smith	A Rumble at Rio Tinto In just a few months, London-based mining and minerals giant Rio Tinto has gone from the penthouse to the outhouse.
The Motley Fool February 10, 2009	2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Kimberly Clark Corp. ... Sierra Wireless, Inc. ...
The Motley Fool February 10, 2009 Tim Beyers	Is This Apple's Next Big Idea? In a recent interview, Piper Jaffray analyst Gene Munster told Macworld UK to expect an Apple-branded TV soon.
The Motley Fool February 10, 2009 Anders Bylund	Nam Tai Is Right to Be Cocky Nam Tai will come roaring back in the end, reinstating dividends and regaining investor confidence. Their operating record will once again speak for itself.
The Motley Fool February 10, 2009 Brian Orelli	Roses and Candy From the FDA? Some drugmakers expect the FDA to bestow its kiss of approval this month. Read on to see who.
The Motley Fool February 10, 2009 Rick Aristotle Munarriz	Eye on Cramer: Monday This analyst promises to watch an entire week of CNBC's Mad Money, just for the sake of having someone else out there in the financial community provide a counterpoint to Jim Cramer's theatrical advice.
<Older 34591-34600 Newer> Return to current articles.